Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 27, 2021
Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative PatientsDustin R Long, Saurabh Gombar, Catherine A Hogan, et al.
Research Square|July 24, 2020
B cell clonal expansion and convergent antibody responses to SARS-CoV-2Sandra C A Nielsen, Fan Yang, Ramona A Hoh, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Occurrence and Timing of Subsequent SARS-CoV-2 RT-PCR Positivity Among Initially Negative PatientsDustin R Long, Saurabh Gombar, Catherine A Hogan, et al.
JCI Insight|July 25, 2020
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsisJennifer G Wilson, Laura J Simpson, Anne-Maud Ferreira, et al.
Science Translational Medicine|September 22, 2022
SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophagesGiovanny J Martínez-Colón, Kalani Ratnasiri, Heping Chen, et al.
Biorxiv : the Preprint Server for Biology|August 31, 2021
The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamstersTimothy Carroll, Douglas Fox, Neeltje van Doremalen, et al.
Plos Pathogens|February 10, 2022
The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamstersTimothy Carroll, Douglas Fox, Neeltje van Doremalen, et al.
Science Translational Medicine|March 13, 2024
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutationsMichael Westberg, Yichi Su, Xinzhi Zou, et al.
Plos Pathogens|July 17, 2025
Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropismRavi K Dinesh, Chengkun Wang, Yuanhao Qu, et al.
Nature Communications|August 3, 2022
An intranasal ASO therapeutic targeting SARS-CoV-2Chi Zhu, Justin Y Lee, Jia Z Woo, et al.
Pageof 5